<SEC-DOCUMENT>0001193125-18-206538.txt : 20180628
<SEC-HEADER>0001193125-18-206538.hdr.sgml : 20180628
<ACCEPTANCE-DATETIME>20180628071102
ACCESSION NUMBER:		0001193125-18-206538
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180628
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180628
DATE AS OF CHANGE:		20180628

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arsanis, Inc.
		CENTRAL INDEX KEY:			0001501697
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				273181608
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38295
		FILM NUMBER:		18923196

	BUSINESS ADDRESS:	
		STREET 1:		890 WINTER STREET, SUITE 230
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		781-819-5704

	MAIL ADDRESS:	
		STREET 1:		890 WINTER STREET, SUITE 230
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d641974d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): June&nbsp;28, 2018 </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Arsanis,&nbsp;Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-38295</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">27-3181608</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction<BR>of incorporation)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Commission<BR>File Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(IRS Employer<BR>Identification No.)</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>890 Winter Street, Suite 230<BR>Waltham, Massachusetts</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>02451</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (781)
<FONT STYLE="white-space:nowrap">819-5704</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not applicable </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former Name or Former Address, if Changed Since Last Report) </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (<I>see</I> General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">14d-2(b)&nbsp;under</FONT> the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">13e-4(c)&nbsp;under</FONT> the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Emerging growth company&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9746; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;28, 2018, Arsanis, Inc. issued a press release announcing the completion of
a planned interim analysis of its Phase 2 clinical trial of ASN100 for the prevention of <I>S. aureus</I> pneumonia in high-risk, mechanically ventilated patients by an independent data review committee. A copy of this press release is filed as
Exhibit 99.1 to this Form <FONT STYLE="white-space:nowrap">8-K</FONT> and incorporated herein by reference. The information contained on websites referenced in this press release is not incorporated herein. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Exhibits</I> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B><br><B>No.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d641974dex991.htm">Press release dated June&nbsp;28, 2018 </A></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">ARSANIS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: June 28, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael P. Gray</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Michael P. Gray</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Operating Officer and Chief Financial Officer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d641974dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g641974img001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Arsanis Provides Update Following Completion of Planned Interim Analysis </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>of Phase 2 Clinical Trial of ASN100 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Trial Unlikely to Meet Primary Efficacy Endpoint; Arsanis to Cease Trial Enrollment </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>and Evaluate Complete Clinical Trial Dataset </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Arsanis to Continue Focus on Development of ASN500 for Prevention of RSV Infection </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WALTHAM, Mass. and VIENNA, Austria &#150; June</B><B></B><B>&nbsp;28, 2018</B> &#150; Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical
company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced the discontinuation of its Phase 2 clinical trial of ASN100 for the prevention of <I>S. aureus</I> pneumonia in high-risk,
mechanically ventilated patients following the completion of a planned interim analysis of unblinded trial data by an independent data review committee (DRC). Based on the results of this analysis, the DRC determined that the trial was futile,
meaning that it was not likely to meet its primary <FONT STYLE="white-space:nowrap">end-point</FONT> upon completion and recommended that trial enrollment be discontinued. Arsanis intends to conduct <FONT STYLE="white-space:nowrap">follow-up</FONT>
visits on all patients dosed with ASN100 per the study protocol. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are disappointed that this clinical study was futile despite the survival
benefit of ASN100 as compared to placebo observed in preclinical models of pneumonia, however Arsanis remains confident in the potential of monoclonal antibodies to prevent and treat serious infections, while also reducing the threat of antibiotic
resistance,&#148; said Ren&eacute; Russo, President and Chief Executive Officer of Arsanis. &#147;We intend to evaluate the complete dataset from the patients that were enrolled in the ASN100 study to better understand the basis for this result and
expect to provide an update on the program following this review. We thank the patients and their caregivers who participated in the ASN100 Phase 2 study.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Russo continued, &#147;We will continue to focus our efforts and resources on our other programs, including the development of ASN500 for the
prevention of respiratory syncytial virus (RSV) infection, which contributes to 240,000 hospitalizations per year in the U.S. <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> data for ASN500 has demonstrated high potency with potential to offer
benefits over existing preventive therapies in terms of dosing strategy, manufacturing and route of administration, to better serve both new and existing target patient populations. We expect to advance ASN500 into Phase 1 clinical trials in
2019.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the ASN100 Phase 2 Clinical Trial </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ASN100 Phase 2 clinical trial was a double-blind, placebo-controlled superiority trial evaluating the efficacy and safety of ASN100 for the prevention of
<I>S. aureus</I> pneumonia in high-risk, mechanically ventilated patients, an indication for which there are no approved therapies. The primary efficacy endpoint of the trial was the proportion of patients who develop <I>S. aureus</I> pneumonia
through 21 days after dosing. The trial was designed to detect a 50% reduction in the occurrence of <I>S. aureus</I> pneumonia in the ASN100 arm when compared to placebo. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ASN100 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASN100 is a combination of two <FONT
STYLE="white-space:nowrap">co-administered</FONT> fully human monoclonal antibodies (mAbs), <FONT STYLE="white-space:nowrap">ASN-1</FONT> and <FONT STYLE="white-space:nowrap">ASN-2,</FONT> that together neutralize the six cytotoxins critical to
<I>S. aureus</I> pneumonia pathogenesis. <FONT STYLE="white-space:nowrap">ASN-1</FONT> neutralizes alpha-hemolysin (Hla), a cytotoxin that damages lung epithelial cells, and four leukocidins, cytotoxins that destroy human immune cells:
gamma-hemolysin AB (HlgAB), gamma-hemolysin CB (HlgCB), Panton-Valentine leukocidin (PVL), and leukocidin ED (LukED). <FONT STYLE="white-space:nowrap">ASN-2</FONT> neutralizes the fifth leukocidin, LukGH, a particularly potent human cytotoxin also
responsible for the destruction of human immune cells. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About&nbsp;Arsanis </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arsanis, Inc. is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious
diseases. A deep understanding of the pathogenesis of infection, paired with access to some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to further its goal of building and advancing a pipeline
of novel mAbs with multiple mechanisms of action and high potency against their intended targets. The Company&#146;s pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g641974img001.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with a wholly owned subsidiary that is
primarily focused on discovery research in Vienna, Austria (Arsanis Biosciences GmbH). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit the Arsanis website at
www.arsanis.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary note regarding forward-looking statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial
risks and uncertainties, including statements regarding: the planned analysis of data from the ASN100 trial; the potential benefits of monoclonal antibodies to prevent and treat serious infections, while reducing the threat of antibiotic resistance
generally; plans and prospects for ASN500; and statements regarding Arsanis&#146; strategy, prospects, plans and objectives of management. The words &#147;anticipate,&#148; &#147;advance,&#148; &#147;believe,&#148; &#147;continue,&#148;
&#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;look forward,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148;
&#147;target,&#148; &#147;would,&#148; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from
the plans, intentions and expectations disclosed in the forward-looking statements Arsanis&#146; makes as a result of important factors, including, but not limited to: uncertainties inherent in the availability and timing of data from the stopped
Phase 2 trial of ASN100; Arsanis&#146; ability to advance the development of its programs under the timelines it projects, demonstrate the requisite safety, efficacy and combinability of its drug candidates and/or replicate scientific and <FONT
STYLE="white-space:nowrap">non-clinical</FONT> data in clinical trials; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities and investigational review boards at clinical trial sites;
Arsanis&#146; ability to obtain and maintain requisite regulatory approvals; competitive factors; Arsanis&#146; ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing;
the availability of cash resources, Arsanis&#146; ability to manage expenses, and its need for additional financing; Arsanis&#146; ability to successfully execute on its business strategies; and other important risk factors as set forth in filings
that Arsanis periodically makes with the U.S. Securities Exchange Commission, or SEC, including the risk factors described under the caption &#147;Risk Factors&#148; in its Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the
year ended December&nbsp;31, 2017, as updated in its Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2018, each of which is on file with the SEC. The forward-looking statements contained in
this press release reflect the current views of Arsanis with respect to future events, and Arsanis assumes no obligation to update any forward-looking statements except as required by applicable law.<I> </I><I></I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jennifer Paganelli, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">347-658-8290</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><U>jpaganelli@purecommunications.com</U><I></I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Gray, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">781-819-5201</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Operating and Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>mike.gray@arsanis.com </U></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g641974img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g641974img001.jpg
M_]C_X  02D9)1@ ! 0$"6 )8  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0
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MR^ O''Q$\,0^'/!?Q$N/!QFND_M&[MH?,FFM.0\<;Y!C8YX(^AKR^/\ 8'^
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M$9/D<4W?1M_%ONON/DC4/$VG_L\_MA>)O%OQ&WV/A?XB:9;QV.M/&S003Q!
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
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
